Kiniksa (KNSA) CEO Sanj K. Patel Exercises Options; Tax Withholding

What Happened

• Sanj K. Patel, Chairman & CEO of Kiniksa Pharmaceuticals (KNSA), reported multiple derivative exercises and awards on Sept 1, 2026. The filing shows conversions/exercises of derivatives totaling 31,318 shares (9,991 + 6,481 + 6,237 + 8,609) and two grants of RSUs totaling 150,200 shares (30,050 and 120,150).
• To satisfy tax withholding, 15,144 shares were disposed (withheld) at a reported withholding value of $79.28 per share, totaling $1,200,616. Several exercised/converted derivative entries are reported as $0 (derivative transactions/settlements) and the RSU grants are reported at $0 (compensation awards).

Key Details

• Transaction date: September 1, 2026; Form filed September 3, 2026 (appears timely).
• Tax withholding: 15,144 shares withheld at $79.28/share = $1,200,616 (code F).
• Derivative exercises/conversions: 9,991; 6,481; 6,237; 8,609 shares (codes M, some reported as acquired and some shown as disposed $0 for derivative settlement).
• RSU grants (code A): 30,050 and 120,150 RSUs granted at $0 (total 150,200 RSUs).
• Shares owned after the transactions: not stated in the provided summary of the filing.
• Relevant footnotes: F1 = each RSU converts to one Class A ordinary share; F2–F7 describe four-year vesting schedules for RSU grants (annual 25% vesting on grant anniversaries) and F3 describes option vesting schedule (25% after one year then monthly over 36 months).

Context

• These filings reflect compensation-related activity: exercises/conversions of derivative awards and new RSU grants, not an open-market purchase or sale by the insider. The withholding of 15,144 shares to cover taxes is a common cashless/net settlement practice when awards vest or options are exercised; it reduces the net shares delivered to the insider.
• Awards and tax-withholdings are routine insider-compensation events and do not by themselves indicate a buy or sell sentiment.